Biosearch Enterprise Value
Delisted
The Enterprise Value (EV) of Biosearch (BIO.MC) as of Jul 26, 2026 is 126.97 M EUR. In the previous year, Enterprise Value (EV) was 127.69 M EUR — a change of -0.57% (lower).
Get this data via API
Financial Data API
Enterprise Value
126.97 MEUR
YoY
-0.57%
Last updated:
Enterprise Value (EV) of Biosearch is 2026 126.97 M EUR. Enterprise Value (EV) of Biosearch was 2025 127.69 M EUR. It decreases by -0.57% lower compared to the previous year.
Access this data via the Eulerpool API
Biosearch Stock analysis
What does Biosearch do? Biosearch SA is a Spanish company specializing in the development, production, and distribution of nutrients for the healthcare industry. The company was founded in 1993 and is headquartered in Granada, Spain. Since then, it has played a significant role in the industry and is now considered one of the leading providers of products for the healthcare sector. Biosearch is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Biosearch stock
Enterprise Value (EV) of Biosearch is 126.97 M EUR in 2026.
Access this data via the Eulerpool API
Valuation — Biosearch
All Key Metrics — Biosearch
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth